Indeed, because of improved pharmacokinetics (e.g., longer half-life, greater tumor uptake), nanoparticles can deliver higher drug concentrations to the tumor site while limiting the accumulation in healthy tissue [2] and biotherapies, such as monoclonal antibodies or more recent immune checkpoint inhibitors, address new therapeutic targets (e.g., HER2, EGFR, CTLA-4, PD-1, and PD-L1) which is essential for a better cure and long-term survival [1,3]. This evidence concerns the gene CTLA4 and neoplasm.